SanBio Company Limited
JPX: 4592.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Keita Mori
- Employees
- 29
- Headquarters
- Tokyo, Japan
- IPO year
- 2015
- Market cap
- ¥176.2B
- Website
- https://www.sanbio.jp
Loading 4592…
Loading profile data…Frequently asked questions about 4592
What does SanBio Company Limited (4592.T) do?
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-relate...
Where does 4592.T trade?
SanBio Company Limited (4592.T) trades on the Tokyo Stock Exchange.
What sector is 4592.T in?
SanBio Company Limited (4592.T) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of SanBio Company Limited?
Keita Mori is the chief executive officer of SanBio Company Limited (4592.T).
Where is SanBio Company Limited headquartered?
SanBio Company Limited is headquartered in Japan.
Does 4592.T pay a dividend?
SanBio Company Limited (4592.T) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4592.T go public?
SanBio Company Limited (4592.T) completed its initial public offering in 2015.